23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
Under 23andMe's current user agreement, users must opt-in to allow the company to share their personal DNA or data. The ...
But what can customers of 23andMe themselves do to make sure their highly personal genetic data is protected? And should we ...
23andMe Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, ...
23andMe's woes were further exacerbated by a data breach last year, wherein hackers gained access to personal information ...
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as ...
The genetics company is closing a unit that was once seen as core to its future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback